Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Everolimus for Pediatric Gliomas with PDGFR Alterations
NCT03352427Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2017
- Primary completion
- Apr 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in glioma and diffuse intrinsic pontine glioma (DIPG), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Progression-free Survival in Participants With Newly Diagnosed Diffuse Intrinsic Pontine Glioma at 8 months, Progression-free Survival in Participants With Newly Diagnosed High-grade Glioma at 12 months and 1 more. Started Dec 2017; status: terminated.
02
Drugs
dasatinib
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT03352427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03352427.